Neurocrine Biosciences, Inc. (NBIX) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Company Overview - Neurocrine has had a challenging year, reflecting broader difficulties in the biotech industry, despite a positive stock performance recently [3]. - The company is executing well operationally, indicating strong internal performance amidst external challenges [3]. Industry Context - The biotech sector has faced significant hurdles this year, leading to a general sentiment of struggle within the industry [3]. - There is a recognition that while stock performance may be favorable at the moment, the journey to this point has been arduous for many companies in the sector [3].